» Articles » PMID: 35681674

Surgical Treatment of Bone Sarcoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jun 10
PMID 35681674
Authors
Affiliations
Soon will be listed here.
Abstract

Bone sarcomas are rare primary malignant mesenchymal bone tumors. The three main entities are osteosarcoma, chondrosarcoma, and Ewing sarcoma. While prognosis has improved for affected patients over the past decades, bone sarcomas are still critical conditions that require an interdisciplinary diagnostic and therapeutic approach. While radiotherapy plays a role especially in Ewing sarcoma and chemotherapy in Ewing sarcoma and osteosarcoma, surgery remains the main pillar of treatment in all three entities. After complete tumor resection, the created bone defects need to be reconstructed. Possible strategies are implantation of allografts or autografts including vascularized bone grafts (e.g., of the fibula). Around the knee joint, rotationplasty can be performed or, as an alternative, the implantation of (expandable) megaprostheses can be performed. Challenges still associated with the implantation of foreign materials are aseptic loosening and infection. Future improvements may come with advances in 3D printing of individualized resection blades/implants, thus also securing safe tumor resection margins while at the same time shortening the required surgical time. Faster osseointegration and lower infection rates may possibly be achieved through more elaborate implant surface structures.

Citing Articles

From conventional to cutting edge: an exploration of osteosarcoma treatments.

Sellers G, Poirier M, Mayberry T, Cowan B, Wakefield M, Fang Y Med Oncol. 2025; 42(3):81.

PMID: 39982613 DOI: 10.1007/s12032-025-02629-0.


Machine learning-based individualized survival prediction model for prognosis in osteosarcoma: Data from the SEER database.

Cao P, Dun Y, Xiang X, Wang D, Cheng W, Yan L Medicine (Baltimore). 2024; 103(39):e39582.

PMID: 39331900 PMC: 11441932. DOI: 10.1097/MD.0000000000039582.


Stratifying osteosarcoma patients using an epigenetic modification-related prognostic signature: implications for immunotherapy and chemotherapy selection.

Li Z, Xue Y, Huang X, Xiao G Transl Cancer Res. 2024; 13(7):3556-3574.

PMID: 39145082 PMC: 11319966. DOI: 10.21037/tcr-23-2300.


Redox-active vitamin C suppresses human osteosarcoma growth by triggering intracellular ROS-iron-calcium signaling crosstalk and mitochondrial dysfunction.

Vaishampayan P, Lee Y Redox Biol. 2024; 75:103288.

PMID: 39083898 PMC: 11342202. DOI: 10.1016/j.redox.2024.103288.


[ knockdown enhances osteogenic differentiation of adipose-derived mesenchymal stem cells and accelerates bone defect healing in mice].

Ke Z, Huang Z, He R, Zhang Q, Chen S, Cui Z Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(7):1227-1235.

PMID: 39051068 PMC: 11270651. DOI: 10.12122/j.issn.1673-4254.2024.07.02.


References
1.
Grimer R, Athanasou N, Gerrand C, Judson I, Lewis I, Morland B . UK Guidelines for the Management of Bone Sarcomas. Sarcoma. 2011; 2010:317462. PMC: 3022187. DOI: 10.1155/2010/317462. View

2.
Portney D, Bi A, Christian R, Butler B, Peabody T . Outcomes of Expandable Prostheses for Primary Bone Malignancies in Skeletally Immature Patients: A Systematic Review and Pooled Data Analysis. J Pediatr Orthop. 2020; 40(6):e487-e497. DOI: 10.1097/BPO.0000000000001459. View

3.
ENNEKING W, Dunham W . Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am. 1978; 60(6):731-46. View

4.
Miwa S, Shirai T, Yamamoto N, Hayashi K, Takeuchi A, Tada K . Risk factors for surgical site infection after malignant bone tumor resection and reconstruction. BMC Cancer. 2019; 19(1):33. PMC: 6325841. DOI: 10.1186/s12885-019-5270-8. View

5.
Wagner M, Livingston J, Patel S, Benjamin R . Chemotherapy for Bone Sarcoma in Adults. J Oncol Pract. 2016; 12(3):208-16. DOI: 10.1200/JOP.2015.009944. View